Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BYJournal of Ovarian Research

Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons

  • Renhua Chen1
  • Yue Zhang1
  • Anping Li1
  • Ye Chen2
  • Xiaoyuan Zhang2
  • Wenzhi Shen2
  • Dehong Luo1
  1. 1The Third Affiliated Hospital of Zunyi Medical University (The First People’s Hospital of Zunyi)
  2. 2Shandong Provincial Precision Medicine Laboratory for Chronic Non-communicable Diseases, Institute of Precision Medicine, Jining Medical University
Read full textDOICite

Abstract

This review provides an in-depth analysis of the key regulatory pathways involving endothelin-1 (ET-1) and its receptors in the progression of ovarian cancer. As one of the most common malignancies affecting the female reproductive system, ovarian cancer exhibits complex pathogenesis and limited treatment options, making it a critical focus in oncology research. ET-1, a potent vasoconstrictive peptide with diverse biological functions, is implicated not only in normal physiological processes but also plays a pivotal role in ovarian cancer initiation, progression, invasion, metastasis, and chemoresistance. The article begins by outlining the fundamental features of ovarian cancer, including its major histopathological subtypes, incidence, and mortality rates. It then examines the structural and functional aspects of ET-1 and its receptors, elucidating their multifaceted roles in ovarian cancer pathobiology, such as promoting tumor cell proliferation, inhibiting apoptosis, inducing angiogenesis, facilitating epithelial–mesenchymal transition (EMT), mediating chemotherapy resistance, and enhancing cell adhesion and invasion. Furthermore, the review highlights the therapeutic potential of targeting ET-1 signaling pathways, encompassing strategies such as inhibition of ET synthesis, receptor antagonism, and combination therapies. Finally, it discusses future research directions aimed at advancing precision medicine approaches for ovarian cancer treatment.

Related

  1. Editorial: Decoding cancer complexity with artificial intelligence and molecular level studies: informatics-driven approaches for therapeutic innovation
    Chandrabose Selvaraj, Krishnendu Bera, Senthilkumar Krishnamoorthi +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  2. Endothelin signaling in diabetic kidney disease: therapeutic targeting and translational advances
    Li Ma, Wenhua Liu, Xiaotong Wang +2
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Full textEndocrinology & metabolismCrossrefDOAJ
  3. Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer’s disease
    Min Song, Anxu Liu, Hao Liang +4
    Frontiers in NeurologyPeer-reviewedCC BY 4.0NeurologyCrossref
  4. Infantile-Onset Pompe Disease: Current Therapeutic Landscape, Clinical Challenges, and Future Horizons.
    Karolina Wyzkiewicz, Klaudia Zinkowska, Veronika Kobylianska +7
    CureusPeer-reviewedCC BYFull textPhysiologyEurope PMC
  5. Translational lipidomics in glaucoma: mechanisms, biomarkers, and therapeutic horizons
    Abu Bakar Butt, Michael Balas, Jeremy M. Sivak +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossref

Cite

BibTeXRIS
BibTeX
@article{chen2026decoding,
  title = {{Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons}},
  author = {Renhua Chen and Yue Zhang and Anping Li and Ye Chen and Xiaoyuan Zhang and Wenzhi Shen and Dehong Luo},
  journal = {Journal of Ovarian Research},
  year = {2026},
  month = jul,
  doi = {10.1186/s13048-026-02216-5},
  url = {https://doi.org/10.1186/s13048-026-02216-5},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons
AU  - Renhua Chen
AU  - Yue Zhang
AU  - Anping Li
AU  - Ye Chen
AU  - Xiaoyuan Zhang
AU  - Wenzhi Shen
AU  - Dehong Luo
PY  - 2026
DA  - 2026/07/01
JO  - Journal of Ovarian Research
DO  - 10.1186/s13048-026-02216-5
UR  - https://doi.org/10.1186/s13048-026-02216-5
AB  - This review provides an in-depth analysis of the key regulatory pathways involving endothelin-1 (ET-1) and its receptors in the progression of ovarian cancer. As one of the most common malignancies affecting the female reproductive system, ovarian cancer exhibits complex pathogenesis and limited treatment options, making it a critical focus in oncology research. ET-1, a potent vasoconstrictive peptide with diverse biological functions, is implicated not only in normal physiological processes but also plays a pivotal role in ovarian cancer initiation, progression, invasion, metastasis, and chemoresistance. The article begins by outlining the fundamental features of ovarian cancer, including its major histopathological subtypes, incidence, and mortality rates. It then examines the structural and functional aspects of ET-1 and its receptors, elucidating their multifaceted roles in ovarian cancer pathobiology, such as promoting tumor cell proliferation, inhibiting apoptosis, inducing angiogenesis, facilitating epithelial–mesenchymal transition (EMT), mediating chemotherapy resistance, and enhancing cell adhesion and invasion. Furthermore, the review highlights the therapeutic potential of targeting ET-1 signaling pathways, encompassing strategies such as inhibition of ET synthesis, receptor antagonism, and combination therapies. Finally, it discusses future research directions aimed at advancing precision medicine approaches for ovarian cancer treatment.
SN  - 1757-2215
ER  -